Effectiveness of companion-intensive multi-aspect weight management in Chinese adults with obesity: a 6-month multicenter randomized clinical trial

Jiang, Wanzi; Huang, Shushu; Ma, Shuai; Gong, Yingyun; Fu, Zhenzhen; Zhou, Li; Hu, Wen; Mao, Guofang; Ma, Zhimin; Yang, Ling; Tang, Guangfeng; Sun, Xiaofang; Zhang, Ping; Bai, Jianling; Chen, Lei; Shi, Bimin; Ye, Xinhua; Zhou, Hongwen

doi:10.1186/s12986-020-00511-6

Table 2 Outcome differences between CIMWM and TMWM groups during the 6-month follow-up period^a

From: Effectiveness of companion-intensive multi-aspect weight management in Chinese adults with obesity: a 6-month multicenter randomized clinical trial

	Time (month)	CIMWM	TMWM	p value^b
Weight loss ≥ 5%	1	30.9% (38/123)	24.4% (32/131)	0.249
	2	68.3% (84/123)	49.6% (65/131)	0.003**
	3	76.4% (94/123)	54.2% (71/131)	< 0.001***
	6	66.7% (82/123)	54.2% (71/131)	0.042*
△BMI (kg/m²)	1	− 1.14 ± 1.17	− 0.96 ± 1.05	0.437
	2	− 2.08 ± 1.21	− 1.46 ± 3.84	0.013*
	3	− 2.58 ± 1.51	− 1.88 ± 2.12	0.006**
	6	− 2.44 ± 1.82	− 1.74 ± 2.59	0.006**
△BW (kg)	1	− 3.65 ± 2.31	− 3.06 ± 3.70	0.438
	2	− 6.30 ± 5.62	− 5.42 ± 7.55	0.260
	3	− 8.09 ± 6.57	− 5.77 ± 7.90	0.004**
	6	− 7.42 ± 8.16	− 6.86 ± 10.67	0.461
△BFP (%)	1	− 1.13 ± 1.50	− 0.60 ± 1.45	0.062
	2	− 1.82 ± 2.14	− 1.33 ± 2.46	0.085
	3	− 2.43 ± 2.77	− 1.89 ± 2.52	0.058
	6	− 2.74 ± 3.26	− 1.94 ± 3.02	0.006**
△BFM (kg)	1	− 2.26 ± 1.79	− 1.51 ± 1.72	0.055
	2	− 3.40 ± 3.13	− 3.02 ± 4.20	0.284
	3	− 4.64 ± 2.80	− 3.67 ± 4.21	0.015*
	6	− 4.62 ± 3.54	− 3.36 ± 5.67	0.002**
△FFM (kg)	1	− 1.44 ± 1.86	− 1.43 ± 3.15	0.873
	2	− 2.73 ± 4.73	− 2.25 ± 4.99	0.498
	3	− 3.86 ± 6.52	− 2.14 ± 5.22	0.004**
	6	− 2.86 ± 5.59	− 2.05 ± 5.15	0.203
△SMM (kg)	1	− 0.78 ± 1.41	− 0.80 ± 1.72	0.871
	2	− 1.29 ± 2.40	− 1.21 ± 2.68	0.925
	3	− 1.08 ± 4.47	− 1.11 ± 2.60	0.855
	6	− 2.06 ± 4.71	− 1.48 ± 3.63	0.149
△VFA (cm²)	1	− 10.86 ± 19.05	− 6.84 ± 25.88	0.028*
	2	− 17.00 ± 21.87	− 14.13 ± 36.58	0.067
	3	− 22.38 ± 23.52	− 18.90 ± 36.28	0.043*
	6	− 23.70 ± 28.21	− 20.45 ± 39.15	0.051
△(S/V) (kg/cm²)	1	0.01 ± 0.05	− 0.01 ± 0.22	0.061
	2	0.03 ± 0.06	− 0.00 ± 0.22	0.012*
	3	0.05 ± 0.07	0.01 ± 0.23	0.002**
	6	0.04 ± 0.08	0.01 ± 0.22	0.008**
△WC (cm)	1	− 2.29 ± 7.22	− 1.35 ± 9.95	0.322
	2	− 6.14 ± 11.56	− 4.19 ± 10.39	0.047*
	3	− 7.12 ± 7.80	− 5.35 ± 11.78	0.071
	6	− 7.33 ± 8.93	− 5.70 ± 12.25	0.095
△HC (cm)	1	− 2.13 ± 4.46	− 0.76 ± 9.84	0.218
	2	− 4.34 ± 5.45	− 4.40 ± 14.24	0.833
	3	− 5.71 ± 5.81	− 4.39 ± 13.94	0.241
	6	− 4.95 ± 5.48	− 3.83 ± 11.09	0.329
△WHR	1	− 0.00 ± 0.07	− 0.06 ± 0.69	0.931
	2	− 0.02 ± 0.10	− 0.04 ± 0.72	0.936
	3	− 0.02 ± 0.08	− 0.05 ± 0.72	0.164
	6	− 0.03 ± 0.08	− 0.07 ± 0.70	0.936
△SBP (mmHg)	1	− 4.92 ± 11.27	− 4.49 ± 12.44	0.483
	2	− 6.38 ± 12.33	− 4.91 ± 13.47	0.136
	3	− 7.11 ± 13.17	− 7.21 ± 12.97	0.772
	6	− 6.66 ± 12.97	− 6.32 ± 13.64	0.531
△DBP (mmHg)	1	− 4.62 ± 10.17	− 4.33 ± 10.31	0.305
	2	− 5.94 ± 9.98	− 4.34 ± 9.83	0.017*
	3	− 6.24 ± 10.19	− 5.73 ± 10.53	0.208
	6	− 5.64 ± 10.25	− 6.14 ± 10.52	0.829
△ALT (U/L)	3	− 14.40 ± 21.74	− 10.61 ± 24.03	0.836
	6	− 14.86 ± 25.98	− 7.94 ± 31.41	0.156
△AST (U/L)	3	− 6.32 ± 10.49	− 4.50 ± 10.08	0.548
	6	− 5.62 ± 12.86	− 2.48 ± 14.37	0.095
△TC (mmol/L)	3	− 0.43 ± 0.94	− 0.18 ± 0.85	0.025*
	6	− 0.43 ± 0.97	− 0.16 ± 0.85	0.013*
△TG (mmol/L)	3	− 0.76 ± 1.79	− 0.60 ± 0.96	0.849
	6	− 0.48 ± 1.63	− 0.30 ± 1.17	0.713
△HDL-C (mmol/L)	3	0.03 ± 0.23	0.02 ± 1.42	0.339
	6	0.10 ± 0.27	0.02 ± 1.15	0.283
△LDL-C (mmol/L)	3	− 0.17 ± 0.65	− 0.06 ± 0.72	0.168
	6	− 0.27 ± 0.67	− 0.15 ± 0.72	0.126
△Lp (a) (mg/L)	3	42.88 ± 149.61	49.15 ± 86.74	0.881
	6	47.91 ± 193.69	25.69 ± 94.77	0.122
△FPG (mmol/L)	3	− 0.26 ± 0.74	− 0.19 ± 1.06	0.674
	6	− 0.23 ± 0.91	− 0.18 ± 1.14	0.756
△Cr (µmol/L)	3	− 1.30 ± 9.39	0.70 ± 11.46	0.448
	6	− 0.61 ± 11.08	− 0.97 ± 14.54	0.282
△UA (µmol/L)	3	5.25 ± 71.00	− 3.48 ± 102.55	0.097
	6	− 34.21 ± 82.14	− 19.11 ± 95.79	0.361
△FINS (pmol/L)	3	− 67.95 ± 192.05	− 39.86 ± 76.70	0.229
	6	− 62.95 ± 194.36	− 32.24 ± 73.93	0.107
△FCP (pmol/L)	3	− 385.4 ± 1244.23	− 120.41 ± 698.46	0.382
	6	− 421.05 ± 1219.72	− 197.40 ± 450.50	0.872
△HbA1c (%)	3	− 0.17 ± 0.31	− 0.09 ± 0.36	0.117
	6	− 0.04 ± 0.41	− 0.02 ± 0.45	0.885
△HOMA-IR	3	− 2.35 ± 6.01	− 1.37 ± 2.76	0.182
	6	− 2.17 ± 6.08	− 1.12 ± 2.74	0.103
△NFS	3	0.01 ± 0.71	− 0.10 ± 0.86	0.749
	6	− 0.02 ± 0.74	− 0.03 ± 1.02	0.649

BMI body mass index, BW body weight, BFP body fat percentage, BFM body fat mass, FFM fat-free mass, SMM skeletal muscle mass, VFA visceral fat area, S/V skeletal muscle mass-to-visceral fat area radio, WC waist circumference, HC hip circumference, WHR waist-to-hip ratio, ALT alanine aminotransferase, AST aspartate aminotransferase, TC total cholesterol, TG triglyceride, HDL-C high-density lipoprotein cholesterol, LDL-C low-density lipoprotein cholesterol, [Lp(a)]Lipoprotein(a), Cr creatinine, UA uric acid, FPG fasting plasma glucose, FINS fasting insulin, FCP fasting C peptide, HbA1c glycated hemoglobin, NFS non-alcoholic fatty liver disease score, SBP systolic blood pressure, DBP diastolic blood pressure, HOMA-IR homeostasis model assessment of insulin resistance
^aData are represented as mean ± SD for continuous variables and as percentages for categorical variables
^bBetween-group differences were analyzed using mixed model controlling for baseline index; categorical variables of individuals with weight loss ≥ 5% were analyzed using chi-square analysis
*p < 0.05, **p < 0.01, ***p < 0.001

Back to article page

ISSN: 1743-7075

Contact us

General enquiries: journalsubmissions@springernature.com

Nutrition & Metabolism

Contact us